Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 8/20 | 0.40 |
| ▸ | APOL1 | O14791 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484795 | 0.85 | MAPT (0.42) | HPGDS | |
| SCHEMBL29629679 | 0.85 | MAPT (0.42) | HPGDS | |
| SCHEMBL30656206 | 0.84 | APOL1 (0.49) | HPGDSAPOL1CDK1MAPKAPK2HPGD | |
| SCHEMBL30656145 | 0.82 | APOL1 (0.42) | HPGDSAPOL1 | |
| SCHEMBL30656139 | 0.82 | ESR1 (0.34) | HPGDSRAB9ANPC1 | |
| SCHEMBL30656106 | 0.82 | ESR1 (0.34) | HPGDSRAB9ANPC1 | |
| SCHEMBL30656127 | 0.81 | SLC6A5 (0.42) | — | |
| SCHEMBL26661131 | 0.81 | SSTR4 (0.36) | — | |
| SCHEMBL30656065 | 0.81 | SSTR4 (0.36) | — | |
| SCHEMBL26792683 | 0.81 | SSTR4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | claimed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | claimed |
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | claimed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | HPGDS 854/4885APOL1 4787/4885RAB9A 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.